GlaxoSmithKline PLC has enjoyed an extended life for its blockbuster respiratory brand Advair Diskus (fluticasone/salmeterol) beyond its patent expiry and transitioned patients to newer medicines in the interim, but the company might be about to hit the end of the road on Advair’s exclusivity in the US.
During the company’s fourth quarter earnings call Feb. 8, CEO Andrew Witty braced investors to expect a substantial hit to...







